Cambrex Invests in New Capacity and Continuous Flow Technology at its Karlskoga, Sweden Facility

East Rutherford, NJ – May 30, 2017 – Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has expanded large scale manufacturing capacity at its cGMP facility in Karlskoga, Sweden and has introduced additional continuous flow manufacturing for the production of high purity intermediates.

The expansion includes the installation of new multi-purpose reactors ranging from 4m 3 to 12m 3 and upgrading of the control room within an existing plant on site. This extra capacity increases the large scale manufacturing capabilities of the Karlskoga facility, which supports clients’ development projects from R&D through to large scale commercial manufacturing. Installation of all new equipment, including a 9m³ hydrogenation reactor, is expected to be completed by Q3 2017.

In addition to the capacity investment at the Karlskoga site, Cambrex has introduced a dedicated continuous flow production unit, capable of producing multiple metric tons of high purity intermediates per annum.

“The additional capacity at the site, within our current infrastructure, will enable us to service our existing and future customers more efficiently,” commented Bjarne Sandberg, Managing Director, Cambrex Karlskoga. He added, “The continuous flow unit builds on our long experience with continuous flow and high energy chemistry and allows for greater production efficiency and flexibility.”

The expansion at Cambrex’s Swedish site is part of an ongoing strategic campaign to invest in small molecule API manufacturing across its global network of facilities.

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals.

Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances.  For more information, please visit

Contact: Alex Maw
Director, Marketing and Communications
Tel: +44 7803 443 155

Posted by Hannah McLachlan